Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells Proliferation

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Tirado Vélez, José Manuel ^a   Joumady, Insaf ^a   Sáez Benito, Ana ^a   Cózar Castellano, Irene ^a   Perdomo, Germán ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ETOMOXIR; FATTY ACID; GLUCOSE; PROTEIN P21; RETINOBLASTOMA PROTEIN; TETRAHYDROLIPSTATIN;

ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; G1 PHASE CELL CYCLE CHECKPOINT; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MYELOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BORONIC ACIDS; CARBOHYDRATE METABOLISM; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CERULENIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; EPOXY COMPOUNDS; FATTY ACIDS; G1 PHASE CELL CYCLE CHECKPOINTS; GLUCOSE; HUMANS; LACTONES; LIPID METABOLISM; MULTIPLE MYELOMA; OXIDATION-REDUCTION; PYRAZINES; RETINOBLASTOMA PROTEIN;

EID: 84866976187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046484     Document Type: Article

References (36)

1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB, (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
2. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
3. Warburg O, (1956) On respiratory impairment in cancer cells. Science 124: 269-270.
4. Ortega AD, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, et al. (2009) Glucose avidity of carcinomas. Cancer Lett 276: 125-135.
5. Menendez JA, Lupu R, (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
6. Yecies JL, Manning BD, (2010) Chewing the fat on tumor cell metabolism. Cell 140: 28-30.
7. Brown NF, Stefanovic-Racic M, Sipula IJ, Perdomo G, (2007) The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 56: 1500-1507.
8. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, et al. (2005) The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173.
9. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, et al. (2002) Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 16: 1550-1557.
10. Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA, Takane KK, Garcia-Ocana A, et al. (2006) Molecular control of cell cycle progression in the pancreatic beta-cell. Endocr Rev 27: 356-370.
11. Schmidt-Schweda S, Holubarsch C, (2000) First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 99: 27-35.
12. Bristow M, (2000) Etomoxir: a new approach to treatment of chronic heart failure. Lancet 356: 1621-1622.
13. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW, (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070-2075.
14. Menendez JA, Vellon L, Lupu R, (2005) Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16: 1253-1267.
15. Pallasch CP, Schwamb J, Konigs S, Schulz A, Debey S, et al. (2008) Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 22: 585-592.
16. Lupu R, Menendez JA, (2006) Pharmacological inhibitors of Fatty Acid Synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol 7: 483-493.
17. Hubinger A, Knode O, Susanto F, Reinauer H, Gries FA, (1997) Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM. Horm Metab Res 29: 436-439.
18. Hubinger A, Weikert G, Wolf HP, Gries FA, (1992) The effect of etomoxir on insulin sensitivity in type 2 diabetic patients. Horm Metab Res 24: 115-118.
19. Berge K, Tronstad KJ, Bohov P, Madsen L, Berge RK, (2003) Impact of mitochondrial beta-oxidation in fatty acid-mediated inhibition of glioma cell proliferation. J Lipid Res 44: 118-127.
20. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, et al. (2008) Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 123: 476-483.
21. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, et al. (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120: 142-156.
22. Wang WQ, Zhao XY, Wang HY, Liang Y, (2008) Increased fatty acid synthase as a potential therapeutic target in multiple myeloma. J Zhejiang Univ Sci B 9: 441-447.
23. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP, (2002) C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A 99: 9498-9502.
24. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, et al. (2011) Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 25: 1041-1051.
25. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M, (2008) The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 68: 5198-5205.
26. Bergsagel PL, Kuehl WM, (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23: 6333-6338.
27. Quinn J, Glassford J, Percy L, Munson P, Marafioti T, et al. (2010) APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 117: 890-901.
28. Vander Heiden MG, (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
29. Vetter ML, Faulconbridge LF, Webb VL, Wadden TA, (2010) Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol 6: 578-588.
30. Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, et al. (2004) Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol 53: 51-60.
31. Tirado-Velez JM, Benitez-Rondan A, Cozar-Castellano I, Medina F, Perdomo G, (2012) Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells. Ann Hematol 91: 83-88.
32. Bligh EG, Dyer WJ, (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
33. Perdomo G, Commerford SR, Richard AM, Adams SH, Corkey BE, et al. (2004) Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation. J Biol Chem 279: 27177-27186.
34. Cozar-Castellano I, Harb G, Selk K, Takane K, Vasavada R, et al. (2008) Lessons from the first comprehensive molecular characterization of cell cycle control in rodent insulinoma cell lines. Diabetes 57: 3056-3068.
35. Tirado-Velez JM, Benitez-Rondan A, Cozar-Castellano I, Medina F, Perdomo G (2011) Low-density lipoprotein cholesterol suppresses apoptosis in human multiple myeloma cells. Ann Hematol.
36. Cozar-Castellano I, Takane KK, Bottino R, Balamurugan AN, Stewart AF, (2004) Induction of beta-cell proliferation and retinoblastoma protein phosphorylation in rat and human islets using adenovirus-mediated transfer of cyclin-dependent kinase-4 and cyclin D1. Diabetes 53: 149-159.